ArticleHealth affairs (Project Hope)2019
Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
Article in Health affairs (Project Hope), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Medication for Adolescents and Young Adults With Opioid Use Disorder.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2021Guideline
- Adapting psychotherapy in collaborative care for treating opioid use disorder and co-occurring psychiatric conditions in primary care.Families, systems & health : the journal of collaborative family healthcare · 2023Trial
- Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention.Journal of substance abuse treatment · 2022Trial
- Exploring the Perspectives of Peer Recovery Specialists: Needs for Training, Support, and Professional Development.Substance use & addiction journal · 2026Article
- Morphine and nicotine intake in high drinking in the dark mice is reduced by informatics-nominated and translationally relevant compounds.Frontiers in psychiatry · 2026Article
- What is necessary for implementation science to actually improve the state of addiction treatment and research?Journal of substance use and addiction treatment · 2025Article
- The impact of psychostimulant use on office based buprenorphine treatment retention.Harm reduction journal · 2025Article
- Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals.JAMA network open · 2025Article
- Opioid and alcohol use disorder medication availability in outpatient care: national estimates & potential policy levers.Health affairs scholar · 2025Article
- Comprehensive drug policies increase trust in local government: an analysis of authorities' and residents' perspectives in rural US Appalachian and Midwestern counties.Harm reduction journal · 2025Article
- Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020.Journal of substance use and addiction treatment · 2025Article
- Factors affecting problem-solving court team decisions about medications for opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Organization of primary care and early MOUD discontinuation.Addiction science & clinical practice · 2024Article
- Medications for opioid use disorders among incarcerated persons and those in the community supervision setting: exploration of implementation issues with key stakeholders.Addiction science & clinical practice · 2024Article
- Barriers and facilitators to implementing CareConnect: A telehealth, low-barrier buprenorphine bridge clinic in Philadelphia.The International journal on drug policy · 2024Article
- Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population-based study.Pharmacotherapy · 2024Article
- Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review.Journal of substance use and addiction treatment · 2024Article
- Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.Journal of substance use and addiction treatment · 2024Article
- "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.Harm reduction journal · 2024Article
- Improving the quality of counseling and clinical supervision in opioid treatment programs: how can technology help?Addiction science & clinical practice · 2024Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Medication treatment (MT) is one of the few evidence-based strategies proposed to combat the current opioid epidemic. We examined national trends and correlates of offering MT in substance use treatment facilities in the United States. According to data from national surveys, the proportion of these facilities that offered any MT increased from 20.0 percent in 2007 to 36.1 percent in 2016-mainly the result of increases in offering buprenorphine and extended-release naltrexone. Only 6.1 percent of facilities offered all three MT medications in 2016. Facilities in states with higher opioid overdose death rates, facilities that accepted health insurance overall (and, more specifically, those that accepted Medicaid in states that opted to expand eligibility for Medicaid), and facilities in states with more comprehensive coverage of MT under their Medicaid plans had higher odds of offering MT. The findings highlight the persistent unmet need for MT nationally and the role of expansion of health insurance in the dissemination of these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.